MiniMed Group Inc (NASDAQ:MMED) Receives Average Recommendation of “Moderate Buy” from Analysts

MiniMed Group Inc (NASDAQ:MMED) has earned an average recommendation of “Moderate Buy” from the sixteen research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $23.7692.

A number of equities research analysts have commented on the company. BTIG Research raised their price target on MiniMed Group from $25.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday. Mizuho upped their target price on shares of MiniMed Group from $21.00 to $26.00 and gave the stock an “outperform” rating in a research report on Wednesday. Wells Fargo & Company raised their target price on shares of MiniMed Group from $22.00 to $26.00 and gave the company an “overweight” rating in a research note on Wednesday. Morgan Stanley lifted their price target on shares of MiniMed Group from $19.00 to $21.00 and gave the company an “overweight” rating in a report on Thursday. Finally, Weiss Ratings upgraded shares of MiniMed Group from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 20th.

More MiniMed Group News

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Better fiscal Q1 performance: MiniMed reported higher-than-expected first-quarter sales, while fiscal Q1 EPS was reported at $0. The results helped drive the shares higher and prompted analysts to raise their forecasts. Analysts boost forecasts following Q1 sales results MiniMed shares rise after higher fiscal Q1 results
• Positive Sentiment: Broad analyst support: UBS raised its target from $25 to $28 and retained a “buy” rating; Bank of America lifted its target from $24 to $28; Mizuho increased its target from $21 to $26; Wells Fargo raised its target from $22 to $26; and Citigroup moved from $23 to $26, maintaining or initiating bullish ratings. Morgan Stanley also raised its target from $19 to $21 and assigned an “overweight” rating. The revisions signal improved expectations after the quarterly sales update, although Morgan Stanley’s target remains below the current trading level. Analyst expectations for MiniMed shares
• Positive Sentiment: Product and regulatory momentum: Coverage highlights a strong start to fiscal 2027, continued product development, and regulatory progress. A fresh product cycle and a greater contribution from recurring revenue could improve growth visibility and support investor confidence. MiniMed starts fiscal 2027 strongly Recurring revenues and fresh product cycle
• Neutral Sentiment: Valuation and execution remain considerations: The stock is trading close to its 52-week high after a substantial advance, leaving less room for disappointment. Investors will likely focus on whether product launches, regulatory milestones, and recurring revenue growth can justify the higher expectations.

Institutional Trading of MiniMed Group

Hedge funds have recently modified their holdings of the company. California State Teachers Retirement System purchased a new stake in MiniMed Group during the second quarter valued at $89,000. Legal & General Group Plc bought a new stake in shares of MiniMed Group in the 2nd quarter worth about $91,000. The Manufacturers Life Insurance Company bought a new stake in shares of MiniMed Group in the 2nd quarter worth about $185,000. Punch & Associates Investment Management Inc. purchased a new stake in shares of MiniMed Group during the 2nd quarter valued at about $292,000. Finally, Washington Growth Strategies LLC bought a new position in shares of MiniMed Group in the 2nd quarter valued at about $397,000.

MiniMed Group Stock Up 0.3%

Shares of MMED stock opened at $23.84 on Friday. The company has a market cap of $6.71 billion and a P/E ratio of -35.06. MiniMed Group has a one year low of $10.65 and a one year high of $24.43. The company’s fifty day moving average price is $18.03.

MiniMed Group (NASDAQ:MMED) last issued its earnings results on Wednesday, June 3rd. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.46). The company had revenue of $837.00 million for the quarter. The firm’s quarterly revenue was up 15.6% compared to the same quarter last year. As a group, equities analysts expect that MiniMed Group will post 0.67 earnings per share for the current year.

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.